PMID- 30613959
OWN - NLM
STAT- MEDLINE
DCOM- 20191028
LR  - 20220603
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 145
IP  - 1
DP  - 2019 Jul 1
TI  - Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A 
      meta-analysis.
PG  - 284-294
LID - 10.1002/ijc.32097 [doi]
AB  - Osimertinib is the only Food and Drug Administration-approved third-generation 
      epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI). A 
      meta-analysis was performed to aggregate the mixed results of published clinical 
      trials to assess the efficacy and safety of osimertinib. A systematic search of 
      the PubMed, Web of Science, and Cochrane Library electronic databases was 
      performed to identify eligible literature. The primary endpoints were overall 
      response rate (ORR), disease control rate (DCR), progression-free survival (PFS), 
      and adverse events (AEs). A total of 3,086 advanced nonsmall cell lung cancer 
      (NSCLC) patients from 11 studies have been identified. The aggregate efficacy 
      parameters for treatment-naive patients with EGFR-TKI-sensitizing mutations are 
      as follows: ORR 79% (95% CI 75-84%), DCR 97% (95% CI 95-99%), 6-month PFS 83% 
      (95% CI 80-87%), and 12-month PFS 64% (95% CI 59-69%). The aggregate efficacy 
      parameters for advanced NSCLC harboring T790M mutations after earlier-generation 
      EGFR-TKI therapy are as follows: ORR 58% (95% CI 46-71%), DCR 80% (95% CI 
      63-98%), 6-month PFS 63% (95% CI 58-69%), and 12-month PFS 32% (95% CI 17-47%). 
      EGFR-TKI-naive patients with EGFR-positive mutations tend to have longer median 
      PFS than EGFR-TKI-pretreated counterparts (19.17 vs. 10.58 months). The most 
      common AEs were diarrhea and rash, of which the pooled incidences were 44 and 
      42%, respectively. Generally, osimertinib is a favorable treatment option for 
      previously treated T790M mutation-positive advanced NSCLC as well as a preferable 
      therapy for untreated EGFR mutation-positive advanced NSCLC. Additionally, 
      osimertinib is well tolerated by most patients.
CI  - (c) 2019 The Authors. International Journal of Cancer published by John Wiley & 
      Sons Ltd on behalf of UICC.
FAU - Yi, Lilan
AU  - Yi L
AD  - Department of Oncology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, People's Republic of China.
FAU - Fan, Junsheng
AU  - Fan J
AD  - Department of Oncology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, People's Republic of China.
AD  - Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji 
      University, Shanghai, People's Republic of China.
FAU - Qian, Ruolan
AU  - Qian R
AD  - Department of Oncology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, People's Republic of China.
FAU - Luo, Peng
AU  - Luo P
AUID- ORCID: 0000-0002-8215-2045
AD  - Department of Oncology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, People's Republic of China.
FAU - Zhang, Jian
AU  - Zhang J
AUID- ORCID: 0000-0001-7217-0111
AD  - Department of Oncology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190120
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Acrylamides)
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 3C06JJ0Z2O (osimertinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
CIN - Int J Cancer. 2019 Oct 1;145(7):2006-2007. PMID: 31074838
CIN - Int J Cancer. 2019 Oct 1;145(7):2003-2005. PMID: 31081942
MH  - Acrylamides/adverse effects/pharmacology/*therapeutic use
MH  - Aniline Compounds/adverse effects/pharmacology/*therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/pharmacology/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics
MH  - ErbB Receptors/genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/enzymology/genetics
MH  - *Mutation
MH  - Protein Kinase Inhibitors/adverse effects/pharmacology/therapeutic use
MH  - Randomized Controlled Trials as Topic
PMC - PMC6590181
OTO - NOTNLM
OT  - EGFR
OT  - T790M
OT  - meta-analysis
OT  - nonsmall cell lung cancer
OT  - osimertinib
EDAT- 2019/01/08 06:00
MHDA- 2019/10/29 06:00
PMCR- 2019/06/24
CRDT- 2019/01/08 06:00
PHST- 2018/10/23 00:00 [received]
PHST- 2018/11/22 00:00 [revised]
PHST- 2018/12/12 00:00 [accepted]
PHST- 2019/01/08 06:00 [pubmed]
PHST- 2019/10/29 06:00 [medline]
PHST- 2019/01/08 06:00 [entrez]
PHST- 2019/06/24 00:00 [pmc-release]
AID - IJC32097 [pii]
AID - 10.1002/ijc.32097 [doi]
PST - ppublish
SO  - Int J Cancer. 2019 Jul 1;145(1):284-294. doi: 10.1002/ijc.32097. Epub 2019 Jan 
      20.